The present invention relates to therapeutic antibodies for the treatment of cancer, and more specifically, for the treatment of prostate, bladder, and/or pancreatic cancer. An embodiment of the present invention is an anti-glypican-1 (GPC 1) antibody, which may be conjugated to at least one cytotoxic agent that is toxic to a prostate, bladder, and/or pancreatic cancer cell.